Cortex enters into agreement with the National Institute of Drug Abuse
The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
In a poster on Monday, September 22, "Discovery and characterization of super-enhancer-associated dependencies in acute myeloid leukemia (AML)," Syros scientists demonstrated that by examining the entire genomes of